Rafick Pierre Sekaly
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Rafick Pierre Sekaly has a total of 924 co-authors. Here are the top co-authors by number of shared publications:
- Steven Deeks
Department of Medicine, University of California San Francisco, San Francisco, USA
13 shared publications - Elias El Haddad
Drexel University, Tower Health Hospital, Philadelphia, USA
10 shared publications - Slim Fourati
Department of Medicine, Northwestern University, Feinberg School of Medicine, Chicago, IL, USA.
10 shared publications Susan Pereira Ribeiro
Pathology Advanced Translational Research Unit (PATRU), Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, USA
10 shared publications- Bali Pulendran
Institute for Immunity, Transplantation and Infection, Stanford University School of Medicine, Stanford University, Stanford, USA
9 shared publications Khader Ghneim
Pathology Advanced Translational Research Unit (PATRU), Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, USA
9 shared publications
Latest Publications
- Open Access
- 10 November 2026
- Published by Springer Nature in Nature Microbiology
Env-specific antibodies promote post-treatment control in SIV-infected macaques
Viral latency reversal was observed in simian immunodeficiency virus (SIV)-infected rhesus macaques receiving antiretroviral therapy (ART), CD8α lymphocyte depletion and N-803 immunotherapy. However, this therapeutic approach did not reduce the viral reservoir size and treatment interruption resulted in rapid virus rebound. Here, to address this shortfall, we used four anti-SIV Env-specific rhesus IgG1 monoclonal antibodies (RhmAbs) that recognize unique targets on the SIV envelope. SIV mac239 -infected macaques were treated with ART only (group 1); ART + RhmAbs (group 2); or ART + RhmAbs + CD8α-depletion + N-803 (group 3). Robust latency reversal was only achieved in group 3. Viraemia rebounded in all macaques with similar kinetics after treatment interruption. However, compared with pre-ART viral loads, a greater fold reduction in rebound viraemia was seen in groups 2 and 3 and post-treatment control (PTC) required SIV RhmAbs. CD4 + T cells from macaques with PTC maintained low levels of intact SIV proviruses off ART and expressed increased interferon and decreased TGF-β signalling genes. This antiviral gene expression profile was also observed in CD4 + T cells with lower human immunodeficiency virus (HIV)-DNA content from ART-treated people with HIV. These results suggest that reduced virus production may contribute to PTC following ART interruption and provide a target for immune-based strategies to achieve durable viral control.
- 10 November 2026
- Published by Springer Nature in Nature Microbiology
Open AccessEnv-specific antibodies promote post-treatment control in SIV-infected macaques
Viral latency reversal was observed in simian immunodeficiency virus (SIV)-infected rhesus macaques receiving antiretroviral therapy (ART), CD8α lymphocyte depletion and N-803 immunotherapy. However, this therapeutic approach did not reduce the viral reservoir size and treatment interruption resulted in rapid virus rebound. Here, to address this shortfall, we used four anti-SIV Env-specific rhesus IgG1 monoclonal antibodies (RhmAbs) that recognize unique targets on the SIV envelope. SIV mac239 -infected macaques were treated with ART only (group 1); ART + RhmAbs (group 2); or ART + RhmAbs + CD8α-depletion + N-803 (group 3). Robust latency reversal was only achieved in group 3. Viraemia rebounded in all macaques with similar kinetics after treatment interruption. However, compared with pre-ART viral loads, a greater fold reduction in rebound viraemia was seen in groups 2 and 3 and post-treatment control (PTC) required SIV RhmAbs. CD4 + T cells from macaques with PTC maintained low levels of intact SIV proviruses off ART and expressed increased interferon and decreased TGF-β signalling genes. This antiviral gene expression profile was also observed in CD4 + T cells with lower human immunodeficiency virus (HIV)-DNA content from ART-treated people with HIV. These results suggest that reduced virus production may contribute to PTC following ART interruption and provide a target for immune-based strategies to achieve durable viral control.
- Open Access
Coordinated Cytokine Responses Are Associated With Rapid HIV Reservoir Decay During Acute Treated HIV Infection
Background: The HIV reservoir is established within days of infection and persists despite antiretroviral therapy (ART). Host immune responses associated with early reservoir decay remain poorly defined. Methods: We analyzed > 500 longitudinal blood samples from 67 individuals treated during acute HIV infection. Plasma cytokines and HIV reservoir size (intact and defective DNA) were quantified longitudinally. Cytokine–reservoir relationships were assessed using unsupervised clustering and complementary mixed-effects nonlinear and linear spline models; counterfactual modeling examined how cytokine concentrations at defined timepoints related to subsequent reservoir trajectories. Results: TNF-α, IL-17A, and IL-10 were significantly associated with intact HIV DNA during the first 24 weeks of ART after false-discovery-rate correction. TNF-α showed one of the strongest associations with intact reservoir decay, whereas IL-10 showed the most consistent association across intact and defective HIV DNA. A coordinated cytokine cluster comprising IFN-γ, IL-10, IL-18, and TNF-α was associated with both reservoir measures. Phase-specific and counterfactual analyses further suggested that associations between several cytokines and reservoir dynamics varied with timing during early ART. These relationships persisted after adjustment for ART initiation timing, baseline viremia, initial CD4+ T-cell count, and longitudinal CD4:CD8 ratio. Discussion: Coordinated inflammatory, antiviral, and immunoregulatory cytokine responses are associated with HIV reservoir decay following ART initiation during acute infection, with some relationships varying over time. These findings may inform future stage-specific HIV cure strategies that leverage the timing and balance of antiviral, inflammatory, and immunoregulatory pathways to limit reservoir persistence. Main Summary: In people initiating ART during acute HIV infection, coordinated inflammatory, antiviral, and immunoregulatory cytokine responses were associated with faster HIV reservoir decay, with TNF-α and IL-10 showing particularly strong and consistent associations.
Open AccessCoordinated Cytokine Responses Are Associated With Rapid HIV Reservoir Decay During Acute Treated HIV Infection
Background: The HIV reservoir is established within days of infection and persists despite antiretroviral therapy (ART). Host immune responses associated with early reservoir decay remain poorly defined. Methods: We analyzed > 500 longitudinal blood samples from 67 individuals treated during acute HIV infection. Plasma cytokines and HIV reservoir size (intact and defective DNA) were quantified longitudinally. Cytokine–reservoir relationships were assessed using unsupervised clustering and complementary mixed-effects nonlinear and linear spline models; counterfactual modeling examined how cytokine concentrations at defined timepoints related to subsequent reservoir trajectories. Results: TNF-α, IL-17A, and IL-10 were significantly associated with intact HIV DNA during the first 24 weeks of ART after false-discovery-rate correction. TNF-α showed one of the strongest associations with intact reservoir decay, whereas IL-10 showed the most consistent association across intact and defective HIV DNA. A coordinated cytokine cluster comprising IFN-γ, IL-10, IL-18, and TNF-α was associated with both reservoir measures. Phase-specific and counterfactual analyses further suggested that associations between several cytokines and reservoir dynamics varied with timing during early ART. These relationships persisted after adjustment for ART initiation timing, baseline viremia, initial CD4+ T-cell count, and longitudinal CD4:CD8 ratio. Discussion: Coordinated inflammatory, antiviral, and immunoregulatory cytokine responses are associated with HIV reservoir decay following ART initiation during acute infection, with some relationships varying over time. These findings may inform future stage-specific HIV cure strategies that leverage the timing and balance of antiviral, inflammatory, and immunoregulatory pathways to limit reservoir persistence. Main Summary: In people initiating ART during acute HIV infection, coordinated inflammatory, antiviral, and immunoregulatory cytokine responses were associated with faster HIV reservoir decay, with TNF-α and IL-10 showing particularly strong and consistent associations.
- Open Access
NLRP3 Activation and Impaired TGF-β Anti-Inflammatory Pathways Predict Vascular Risk in PWH on ART
Importance: The immune mechanisms driving vascular disease remain incompletely understood. People with HIV (PWH), even during effective antiretroviral therapy (ART), exhibit persistent immune activation and inflammation, which may contribute to higher rates of vascular disease and mortality compared with people without HIV (PWoH). Leveraging a cohort of U.S. military personnel followed from HIV diagnosis through long-term ART suppression, we sought to identify immunologic pathways underlying increased vascular risk. Objective: To identify plasma biomarkers reflecting distinct immune mechanisms that predict incident vascular outcomes in ART-suppressed PWH. Design: Case-cohort study within the U.S. Military HIV Natural History Study. Setting: Longitudinal, multicenter observational cohort. Participants: A total of 1,002 ART-suppressed PWH (HIV RNA <50 copies/mL) were included, with N=135 vascular event (VE) cases and N=702 controls. Cases encompassed atherosclerotic cardiovascular disease (ASCVD) – coronary artery disease (CAD), myocardial infarction (MI), stroke (CVA), peripheral artery disease (PAD) – and venous thrombotic events (VTE) – deep vein thrombosis (DVT) and pulmonary embolism (PE). Exposures: Thirty-three soluble plasma analytes quantified using a high-sensitivity multiplex assay from samples collected ≥1 year after ART suppression. Main Outcomes and Measures: The primary outcome was incident ASCVD. Associations between cytokine concentrations (individual and clustered) and vascular risk were evaluated using unsupervised clustering, Cox proportional hazards models, and causal inference (to estimate 5-year ASCVD risk under hypothetical cytokine alterations). Mediation analyses assessed direct and indirect effects of key inter-related cytokines. Secondary outcome included any VE (ASCVD plus VTE). Covariates included traditional cardiovascular risk factors, HIV clinical variables, and demographics. False discovery rate (FDR) adjustment was applied using the Benjamini-Hochberg method. Results: Cytokine clusters reflecting NLRP3 inflammasome activation and persistent inflammation (IL-18, IL-6) and individual markers (IL-18: HR=1.89, q=0.007; TGF-β2: HR=0.74, q=0.026) were associated with increased ASCVD risk. IL-18 remained nominally significant after adjusting for traditional risk factors (p<0.05) but did not meet FDR significance (q<0.05). Conclusions and Relevance: NLRP3 inflammasome activation and reduced TGF-β2, indicating loss of anti-inflammatory and repair mechanisms, may contribute to atherogenesis in ART-suppressed PWH. These findings highlight potential interventional targets for mitigating inflammation-driven vascular risk and warrant validation in larger cohorts to inform novel therapeutic strategies. Key Points: Question: Which inflammatory immune pathways are associated with incident atherosclerotic cardiovascular disease in ART-suppressed people with HIV? Findings: In this longitudinal case-cohort study of 1,002 ART-suppressed people with HIV, elevated IL-18 and reduced TGF-β2 were associated with incident ASCVD. Associations were specific to arterial rather than venous events, and IL-18-related risk was partly mediated through IL-6. Meaning: These findings suggest that imbalance between inflammasome-driven inflammation and impaired immune regulation contributes to residual cardiovascular risk in treated HIV.
Open AccessNLRP3 Activation and Impaired TGF-β Anti-Inflammatory Pathways Predict Vascular Risk in PWH on ART
Importance: The immune mechanisms driving vascular disease remain incompletely understood. People with HIV (PWH), even during effective antiretroviral therapy (ART), exhibit persistent immune activation and inflammation, which may contribute to higher rates of vascular disease and mortality compared with people without HIV (PWoH). Leveraging a cohort of U.S. military personnel followed from HIV diagnosis through long-term ART suppression, we sought to identify immunologic pathways underlying increased vascular risk. Objective: To identify plasma biomarkers reflecting distinct immune mechanisms that predict incident vascular outcomes in ART-suppressed PWH. Design: Case-cohort study within the U.S. Military HIV Natural History Study. Setting: Longitudinal, multicenter observational cohort. Participants: A total of 1,002 ART-suppressed PWH (HIV RNA <50 copies/mL) were included, with N=135 vascular event (VE) cases and N=702 controls. Cases encompassed atherosclerotic cardiovascular disease (ASCVD) – coronary artery disease (CAD), myocardial infarction (MI), stroke (CVA), peripheral artery disease (PAD) – and venous thrombotic events (VTE) – deep vein thrombosis (DVT) and pulmonary embolism (PE). Exposures: Thirty-three soluble plasma analytes quantified using a high-sensitivity multiplex assay from samples collected ≥1 year after ART suppression. Main Outcomes and Measures: The primary outcome was incident ASCVD. Associations between cytokine concentrations (individual and clustered) and vascular risk were evaluated using unsupervised clustering, Cox proportional hazards models, and causal inference (to estimate 5-year ASCVD risk under hypothetical cytokine alterations). Mediation analyses assessed direct and indirect effects of key inter-related cytokines. Secondary outcome included any VE (ASCVD plus VTE). Covariates included traditional cardiovascular risk factors, HIV clinical variables, and demographics. False discovery rate (FDR) adjustment was applied using the Benjamini-Hochberg method. Results: Cytokine clusters reflecting NLRP3 inflammasome activation and persistent inflammation (IL-18, IL-6) and individual markers (IL-18: HR=1.89, q=0.007; TGF-β2: HR=0.74, q=0.026) were associated with increased ASCVD risk. IL-18 remained nominally significant after adjusting for traditional risk factors (p<0.05) but did not meet FDR significance (q<0.05). Conclusions and Relevance: NLRP3 inflammasome activation and reduced TGF-β2, indicating loss of anti-inflammatory and repair mechanisms, may contribute to atherogenesis in ART-suppressed PWH. These findings highlight potential interventional targets for mitigating inflammation-driven vascular risk and warrant validation in larger cohorts to inform novel therapeutic strategies. Key Points: Question: Which inflammatory immune pathways are associated with incident atherosclerotic cardiovascular disease in ART-suppressed people with HIV? Findings: In this longitudinal case-cohort study of 1,002 ART-suppressed people with HIV, elevated IL-18 and reduced TGF-β2 were associated with incident ASCVD. Associations were specific to arterial rather than venous events, and IL-18-related risk was partly mediated through IL-6. Meaning: These findings suggest that imbalance between inflammasome-driven inflammation and impaired immune regulation contributes to residual cardiovascular risk in treated HIV.
- Open Access
- 5 August 2026
- Published by Springer Nature in Nature
- Vol. 656 (8128) , 700-711
Virus reactivation in acute and long COVID-19
- 5 August 2026
- Published by Springer Nature in Nature
- Vol. 656 (8128) , 700-711
Open AccessVirus reactivation in acute and long COVID-19
- Open Access
- 8 May 2026
- Published by Elsevier in SSRN Electronic Journal
Bile Acids Mediate Control of Acute Viral Infections Through Epigenetic Enhancement of Antiviral and Trained Immunity
Bile acids (BAs) a complex family of immunometabolites can shape myeloid cell function; their role in antiviral immunity and clinical outcomes in human infection remains unclear. We identified an early plasma specific BA signature that distinguished moderate from severe COVID-19 trajectories (M vs. SCHP) in >1,100 hospitalized patients. Single-cell RNA and ATAC sequencing of PBMCs identified a TGR5⁺ monocyte subset in MCHP characterized by increased chromatin accessibility and expression of interferon-responsive antiviral and MHC class II pathways, and reduced IL-10 signaling. External datasets confirmed enrichment of this program in MCHP and healthy donors. In TGR5⁺ monocytes of MCHP, these BAs synergized with IFN-γ to enhance STAT1 activation, ERK/CREB1 signaling, and H3K27ac; independently promoting trained immunity recall responses. We reveal a previously unrecognized antiviral axis whereby these specific BAs activate TGR5 to drive transcriptional and epigenetic programs associated with upregulation of antiviral responses, trained immunity, and favorable clinical outcomes in COVID-19
- 8 May 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessBile Acids Mediate Control of Acute Viral Infections Through Epigenetic Enhancement of Antiviral and Trained Immunity
Bile acids (BAs) a complex family of immunometabolites can shape myeloid cell function; their role in antiviral immunity and clinical outcomes in human infection remains unclear. We identified an early plasma specific BA signature that distinguished moderate from severe COVID-19 trajectories (M vs. SCHP) in >1,100 hospitalized patients. Single-cell RNA and ATAC sequencing of PBMCs identified a TGR5⁺ monocyte subset in MCHP characterized by increased chromatin accessibility and expression of interferon-responsive antiviral and MHC class II pathways, and reduced IL-10 signaling. External datasets confirmed enrichment of this program in MCHP and healthy donors. In TGR5⁺ monocytes of MCHP, these BAs synergized with IFN-γ to enhance STAT1 activation, ERK/CREB1 signaling, and H3K27ac; independently promoting trained immunity recall responses. We reveal a previously unrecognized antiviral axis whereby these specific BAs activate TGR5 to drive transcriptional and epigenetic programs associated with upregulation of antiviral responses, trained immunity, and favorable clinical outcomes in COVID-19
- Open Access
- 20 March 2026
- Published by Springer Nature in Nature Immunology
- Vol. 27 (4) , 686-699
TGF-β mediates epigenetic control of innate antiviral responses and SIV reservoir size
Immune interventions toward an HIV cure have focused on rejuvenating adaptive immune responses. Herein we provide a framework that features epigenetic programming of myeloid and CD4+ T cells as a major mechanism that promotes decay of the HIV reservoir. Coordinate regulation of gene expression and chromatin accessibility of pathways of innate antiviral immunity was associated with decay of cell-associated viral DNA (CA-vDNA) following analytical treatment interruption in simian immunodeficiency virus-infected rhesus macaques (RMs) treated with anti-IL-10 and anti-PD-1. TGF-β/SMAD signaling in a subset of combo-treated CA-vDNAhi RMs, suppressed this antiviral activity through histone deacetylases, reducing chromatin accessibility of interferon regulatory factors (IRFs) and STATs. Addition of HDAC inhibitors in vitro restored antiviral response in the presence of TGF-β. Induction of IL-6 in CA-vDNAlo RMs amplified the antiviral network through IRF9. We identified an overlapping molecular cascade in HIV elite controllers, who maintain small HIV reservoirs without antiviral treatment. These data provide insights into strategies for HIV cure interventions.
- 20 March 2026
- Published by Springer Nature in Nature Immunology
- Vol. 27 (4) , 686-699
Open AccessTGF-β mediates epigenetic control of innate antiviral responses and SIV reservoir size
Immune interventions toward an HIV cure have focused on rejuvenating adaptive immune responses. Herein we provide a framework that features epigenetic programming of myeloid and CD4+ T cells as a major mechanism that promotes decay of the HIV reservoir. Coordinate regulation of gene expression and chromatin accessibility of pathways of innate antiviral immunity was associated with decay of cell-associated viral DNA (CA-vDNA) following analytical treatment interruption in simian immunodeficiency virus-infected rhesus macaques (RMs) treated with anti-IL-10 and anti-PD-1. TGF-β/SMAD signaling in a subset of combo-treated CA-vDNAhi RMs, suppressed this antiviral activity through histone deacetylases, reducing chromatin accessibility of interferon regulatory factors (IRFs) and STATs. Addition of HDAC inhibitors in vitro restored antiviral response in the presence of TGF-β. Induction of IL-6 in CA-vDNAlo RMs amplified the antiviral network through IRF9. We identified an overlapping molecular cascade in HIV elite controllers, who maintain small HIV reservoirs without antiviral treatment. These data provide insights into strategies for HIV cure interventions.
- Open Access
- 13 March 2026
- Published by Springer Nature in Research Square
IL-10- and TGF-β-driven BCL6 expression suppresses antiviral defenses and renders lymph node T follicular helper cells permissive to HIV infection
Lymph nodes (LNs) constitute a key anatomical sanctuary for HIV. Follicular helper T (Tfh) cells expand early upon infection and represent a principal cellular target for initial viral seeding. Here, we identified the transcription factor BCL6, a Tfh-lineage defining marker, as central in favoring the infection of Tfh cells in LNs during the untreated phase in humans, and for the persistence of the reservoir during ART in non-human primates. In situ and ex vivo analyses of LN from people with HIV (PWH) in absence of antiretroviral therapy (ART) revealed preferential enrichment of viral RNA, total HIV DNA, and intact proviruses within BCL6hi Tfh cells, which also presented significantly lower expression of proteins with antiviral functions (IRF7, MX1, APOBEC3G, pSTAT1). In vitro genetic (genome-wide CRISPR knockouts) and pharmacologic perturbations confirmed that BCL6 enhances the cellular permissiveness of Tfh cells to HIV infection. IL-10 and TGF-β were enriched in LNs from people without HIV (PWoH), and cooperatively induced bona fide BCL6hi Tfh differentiation in vitro, with repressed antiviral pathways. IL-10 and TGF-β blockade limited Tfh differentiation, confirming their contribution to Tfh and LN biology. Human Single Nucleotide Polymorphisms (SNPs) in proximity to genes of the IL-10 and TGF-β pathways were enriched in PWH who controls viremia spontaneously (HIV elite controllers). Importantly, in vivo downmodulation of IL-10 and TGF-β signaling pathways in ART-treated SIV-infected macaques, by using anti–IL-10 and anti–PD-1 therapy, led to reduced frequencies of LN BCL6+ Tfh cells. These Tfh cells expressed significantly higher expression of antiviral machineries, similar to gene signatures found in HIV elite controllers, and resulted in significantly lower SIV reservoir size in LNs. This data highlights that the modulation of the IL-10/TGF-β/BCL6 axis is relevant at early stages upon infection, but also during ART, after the HIV reservoir is already established. In both scenarios it results in higher antiviral machinery and lower HIV seeding and reservoir sizes. Thus, the modulation of these pathways in vivo has potential to alter Tfh biology in LNs leading to HIV reservoir decay, contributing to HIV cure strategies.
- 13 March 2026
- Published by Springer Nature in Research Square
Open AccessIL-10- and TGF-β-driven BCL6 expression suppresses antiviral defenses and renders lymph node T follicular helper cells permissive to HIV infection
Lymph nodes (LNs) constitute a key anatomical sanctuary for HIV. Follicular helper T (Tfh) cells expand early upon infection and represent a principal cellular target for initial viral seeding. Here, we identified the transcription factor BCL6, a Tfh-lineage defining marker, as central in favoring the infection of Tfh cells in LNs during the untreated phase in humans, and for the persistence of the reservoir during ART in non-human primates. In situ and ex vivo analyses of LN from people with HIV (PWH) in absence of antiretroviral therapy (ART) revealed preferential enrichment of viral RNA, total HIV DNA, and intact proviruses within BCL6hi Tfh cells, which also presented significantly lower expression of proteins with antiviral functions (IRF7, MX1, APOBEC3G, pSTAT1). In vitro genetic (genome-wide CRISPR knockouts) and pharmacologic perturbations confirmed that BCL6 enhances the cellular permissiveness of Tfh cells to HIV infection. IL-10 and TGF-β were enriched in LNs from people without HIV (PWoH), and cooperatively induced bona fide BCL6hi Tfh differentiation in vitro, with repressed antiviral pathways. IL-10 and TGF-β blockade limited Tfh differentiation, confirming their contribution to Tfh and LN biology. Human Single Nucleotide Polymorphisms (SNPs) in proximity to genes of the IL-10 and TGF-β pathways were enriched in PWH who controls viremia spontaneously (HIV elite controllers). Importantly, in vivo downmodulation of IL-10 and TGF-β signaling pathways in ART-treated SIV-infected macaques, by using anti–IL-10 and anti–PD-1 therapy, led to reduced frequencies of LN BCL6+ Tfh cells. These Tfh cells expressed significantly higher expression of antiviral machineries, similar to gene signatures found in HIV elite controllers, and resulted in significantly lower SIV reservoir size in LNs. This data highlights that the modulation of the IL-10/TGF-β/BCL6 axis is relevant at early stages upon infection, but also during ART, after the HIV reservoir is already established. In both scenarios it results in higher antiviral machinery and lower HIV seeding and reservoir sizes. Thus, the modulation of these pathways in vivo has potential to alter Tfh biology in LNs leading to HIV reservoir decay, contributing to HIV cure strategies.
- Open Access
- 23 February 2026
- Published by Springer Nature in Communications Medicine
- Vol. 6 (1) , 125
Author Correction: Machine learning models predict long COVID outcomes based on baseline clinical and immunologic factors
- 23 February 2026
- Published by Springer Nature in Communications Medicine
- Vol. 6 (1) , 125
Open AccessAuthor Correction: Machine learning models predict long COVID outcomes based on baseline clinical and immunologic factors
- Top Cited PapersOpen Access
- 12 February 2026
- Published by Springer Nature in Nature Medicine
- Vol. 32 (2) , 505-517
Innate antiviral and immune functions associated with the HIV reservoir decay after anti-PD-1 therapy
Antiretroviral therapy (ART) suppresses HIV but does not eliminate the latent viral reservoir, which persists in programmed cell death protein 1 (PD-1)-expressing CD4+ T cells. Anti-PD-1 therapies have reduced the HIV reservoir in people living with HIV (PLWH) and cancer; however, the individuals who benefit and the mechanisms driving reservoir reduction remain unclear. We performed a prespecified exploratory, longitudinal multiomic profiling of 30 PLWH (29 males and one female) with cancer in the phase 1 CITN-12 clinical trial, in which pembrolizumab was evaluated for safety and preliminary antitumor activity. The therapy was generally well tolerated, with most adverse events graded 1–2 and objective antitumor response observed in five participants (one complete response and four partial responses). Within 24 hours of treatment, we observed an expansion of proliferating HIV-specific effector CD8+ T cells and a decline in plasma TGFβ. Furthermore, among the 14 participants tracked to the end of treatment (ranging from 44 to 315 days after therapy initiation), nine display early induction and sustained expression of interferon-stimulated genes (ISGs), antiviral restriction factors and Toll-like receptor (TLR) signaling and a reduction in the HIV reservoir. Mapping these transcriptomic signatures across more than 1,000 public single-cell RNA sequencing datasets reveals that anti-PD-1-induced programs are present in subsets of across subsets of disease states, indicating that some people already display a heightened antiviral state. Together, these findings define immune pathways that help identify PLWH most likely to experience reservoir decay with anti-PD-1 therapy and suggest that sustained ISG activation may contribute to reservoir reduction and prevention of viral rebound upon ART interruption. ClinicalTrials.gov registration: NCT02595866.
- 12 February 2026
- Published by Springer Nature in Nature Medicine
- Vol. 32 (2) , 505-517
Top Cited PapersOpen AccessInnate antiviral and immune functions associated with the HIV reservoir decay after anti-PD-1 therapy
Antiretroviral therapy (ART) suppresses HIV but does not eliminate the latent viral reservoir, which persists in programmed cell death protein 1 (PD-1)-expressing CD4+ T cells. Anti-PD-1 therapies have reduced the HIV reservoir in people living with HIV (PLWH) and cancer; however, the individuals who benefit and the mechanisms driving reservoir reduction remain unclear. We performed a prespecified exploratory, longitudinal multiomic profiling of 30 PLWH (29 males and one female) with cancer in the phase 1 CITN-12 clinical trial, in which pembrolizumab was evaluated for safety and preliminary antitumor activity. The therapy was generally well tolerated, with most adverse events graded 1–2 and objective antitumor response observed in five participants (one complete response and four partial responses). Within 24 hours of treatment, we observed an expansion of proliferating HIV-specific effector CD8+ T cells and a decline in plasma TGFβ. Furthermore, among the 14 participants tracked to the end of treatment (ranging from 44 to 315 days after therapy initiation), nine display early induction and sustained expression of interferon-stimulated genes (ISGs), antiviral restriction factors and Toll-like receptor (TLR) signaling and a reduction in the HIV reservoir. Mapping these transcriptomic signatures across more than 1,000 public single-cell RNA sequencing datasets reveals that anti-PD-1-induced programs are present in subsets of across subsets of disease states, indicating that some people already display a heightened antiviral state. Together, these findings define immune pathways that help identify PLWH most likely to experience reservoir decay with anti-PD-1 therapy and suggest that sustained ISG activation may contribute to reservoir reduction and prevention of viral rebound upon ART interruption. ClinicalTrials.gov registration: NCT02595866.
- Open Access
- 3 January 2026
- Published by Springer Nature in Communications Medicine
- Vol. 6 (1) , 1
Machine learning models predict long COVID outcomes based on baseline clinical and immunologic factors
Background The post-acute sequelae of SARS-CoV-2 (PASC), also known as long COVID, remain a significant health issue that is incompletely understood. Predicting which acutely infected individuals will develop long COVID is challenging due to the absence of established biomarkers, clear disease mechanisms, or well-defined sub-phenotypes. Machine learning (ML) models may address this gap by leveraging clinical data to enhance diagnostic precision. Methods Clinical data, including antibody titers and viral load measurements collected at the time of hospital admission, are used to predict the likelihood of acute COVID-19 progressing to long COVID. Machine learning models are trained and evaluated for predictive performance. Feature importance analysis is performed to identify the most influential predictors. Results The machine learning models achieve median AUROC values ranging from 0.64 to 0.66 and AUPRC values between 0.51 and 0.54, demonstrating predictive capabilities. Low antibody titers and high viral loads at hospital admission emerge as the strongest predictors of long COVID outcomes. Comorbidities—such as chronic respiratory, cardiac, and neurologic diseases—and female sex are also identified as significant risk factors. Conclusions Machine learning models identify patients at risk for developing long COVID based on baseline clinical characteristics. These models guide early interventions, improve patient outcomes, and mitigate the long-term public health impacts of SARS-CoV-2.
- 3 January 2026
- Published by Springer Nature in Communications Medicine
- Vol. 6 (1) , 1
Open AccessMachine learning models predict long COVID outcomes based on baseline clinical and immunologic factors
Background The post-acute sequelae of SARS-CoV-2 (PASC), also known as long COVID, remain a significant health issue that is incompletely understood. Predicting which acutely infected individuals will develop long COVID is challenging due to the absence of established biomarkers, clear disease mechanisms, or well-defined sub-phenotypes. Machine learning (ML) models may address this gap by leveraging clinical data to enhance diagnostic precision. Methods Clinical data, including antibody titers and viral load measurements collected at the time of hospital admission, are used to predict the likelihood of acute COVID-19 progressing to long COVID. Machine learning models are trained and evaluated for predictive performance. Feature importance analysis is performed to identify the most influential predictors. Results The machine learning models achieve median AUROC values ranging from 0.64 to 0.66 and AUPRC values between 0.51 and 0.54, demonstrating predictive capabilities. Low antibody titers and high viral loads at hospital admission emerge as the strongest predictors of long COVID outcomes. Comorbidities—such as chronic respiratory, cardiac, and neurologic diseases—and female sex are also identified as significant risk factors. Conclusions Machine learning models identify patients at risk for developing long COVID based on baseline clinical characteristics. These models guide early interventions, improve patient outcomes, and mitigate the long-term public health impacts of SARS-CoV-2.